What is the appropriate starting dose and titration schedule for Trintellix (vortioxetine) in an adult with major depressive disorder, including adjustments for CYP2D6 poor metabolizers and tapering recommendations?

Trintellix (Vortioxetine) Dosing and Management

Start Trintellix at 10 mg once daily, increase to 20 mg daily as tolerated for optimal efficacy, and reduce the maximum dose to 10 mg daily in known CYP2D6 poor metabolizers. 1

Starting Dose and Titration

The FDA-approved starting dose is 10 mg once daily, taken without regard to meals 1. This represents the standard initial approach for most adults with major depressive disorder.

Target dose: 20 mg daily should be reached as tolerated, as this demonstrates superior efficacy compared to 10 mg daily 1, 2. Evidence shows:

• Vortioxetine 20 mg/day separated from placebo starting at week 2, while 10 mg did not separate until week 4
• At 8 weeks, 20 mg showed significantly greater MADRS improvement than 10 mg (difference of -1.03 points, p<0.05)
• In flexible-dose studies, 48% of patients were increased to 20 mg after just 1 week, and 64.3% ultimately received 20 mg as their final dose 2

For patients who cannot tolerate higher doses, consider 5 mg daily 1. However, recognize this is a compromise dose with reduced efficacy.

CYP2D6 Poor Metabolizer Adjustments

Maximum dose: 10 mg daily in known CYP2D6 poor metabolizers 1. This is critical because:

• Poor metabolizers have 2.1-fold higher vortioxetine serum concentrations compared to normal metabolizers 3
• Poor metabolizers are 5.1-fold more likely to switch from vortioxetine to alternative antidepressants, likely due to concentration-dependent adverse effects 3
• Vortioxetine is primarily metabolized by CYP2D6, making this polymorphism clinically significant 4, 5

When to consider CYP2D6 testing: Prioritize testing in patients with prior antidepressant intolerance, nonresponse, or those on polypharmacy 6. While not required for all patients, testing before initiating vortioxetine or after poor tolerability can guide dose selection 7, 8.

Dose Adjustments with Drug Interactions

Strong CYP2D6 inhibitors (e.g., bupropion, fluoxetine, paroxetine): Reduce vortioxetine dose by half 1

Strong CYP inducers (e.g., rifampin): Consider increasing vortioxetine dose when coadministered for >14 days, up to 3 times the original dose maximum 1

Discontinuation and Tapering

Vortioxetine can be discontinued abruptly without significant withdrawal syndrome 1. However, for doses of 15 mg or 20 mg daily, reduce to 10 mg daily for one week before full discontinuation if possible 1. This recommendation balances the drug's favorable discontinuation profile with practical risk reduction.

The terminal half-life of approximately 66 hours and steady-state achievement within 2 weeks supports this relatively straightforward discontinuation approach 4.

Monitoring and Duration

Following general antidepressant guidelines 9:

• Assess response within 1-2 weeks of initiation and regularly thereafter
• Modify treatment if inadequate response by 6-8 weeks
• Continue treatment 4-9 months after satisfactory response for first episode
• Consider longer duration (years to lifelong) for patients with ≥2 prior episodes

Common Pitfalls to Avoid

1. Underdosing: Don't settle for 10 mg if the patient tolerates higher doses—20 mg demonstrates superior efficacy 2, 10
2. Ignoring CYP2D6 status: Failure to reduce dose in poor metabolizers leads to increased adverse effects and treatment discontinuation 3
3. Premature discontinuation: Allow adequate trial duration (6-8 weeks) before declaring treatment failure 9
4. Missing drug interactions: Always check for strong CYP2D6 inhibitors (especially bupropion) that require dose reduction 1